BACKGROUND:This meta-analysis aimed to determine whether extracorporeal cardiopulmonary resuscitation (ECPR), compared with conventional cardiopulmonary resuscitation (CCPR), improves outcomes in adult patients with cardiac arrest (CA).DATA RESOURCES: PubMed, EMBASE, Web of Science, and China Biological Medicine Database were searched for relevant articles. The baseline information and outcome data (survival, good neurological outcome at discharge, at 3-6 months, and at 1 year after CA) were collected and extracted by two authors. Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using Review Manager 5.3. RESULTS:In six studies 2 260 patients were enrolled to study the survival rate to discharge and longterm neurological outcome published since 2000. A signifi cant effect of ECPR was observed on survival rate to discharge compared to CCPR in CA patients (RR 2.37, 95%CI 1.63-3.45, P<0.001), and patients who underwent ECPR had a better long-term neurological outcome than those who received CCPR (RR 2.79, 95%CI 1.96-3.97, P<0.001). In subgroup analysis, there was a significant difference in survival to discharge favoring ECPR over CCPR group in OHCA patients (RR 2.69, P=0.001). However, no signifi cant difference was found in IHCA patients (RR 1.84, 95%CI 0.91-3.73, P=0.09).CONCLUSION: ECPR showed a benefi cial effect on survival rate to discharge and long-term neurological outcome over CCPR in adult patients with CA.
A simple and eco-friendly strategy for the synthesis of E-ortho-hydroxystilbenes from two kinds of α,β-unsaturated aromatic lactones is described.
Background: Fulminant myocarditis has a sudden onset and rapid progress, which can easily cause multiple organ failure. Acute kidney injury is a common complication. ECMO (extracorporeal membrane oxygenation) and CRRT (continuous renal replacement therapy) have been used in the treatment of fulminant myocarditis, but the combination of the 2 has an impact on the prognosis. There is still a big controversy. Therefore, the purpose of this randomized controlled trial is to evaluate the nursing effect and long-term efficacy and safety of ECMO combined with CRRT in the treatment of fulminant myocarditis. Methods: This is a prospective randomized controlled trial to study the effectiveness and safety of ECMO combined with CRRT in the treatment of fulminant myocarditis. Approved by the clinical research ethics committee of our hospital. Patients were randomly assigned to 1 of 2 treatment options: Observation indicators include: basic vital signs, laboratory indicators, echocardiographic changes, complications, and outcomes. SPSS 25.0 (Chicago, IL) version statistical software package was used to analyze the data. Discussion: This study will evaluate the nursing effect and long-term efficacy and safety of ECMO combined with CRRT in the treatment of fulminant myocarditis. The results of this experiment will provide clinical evidence for the treatment of fulminant myocarditis with ECMO and CRRT. Ethics and dissemination: Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval was not required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences. OSF Registration number: DOI 10.17605/OSF.IO/PAQBZ.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.